Cargando…

Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors

BACKGROUND: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients. RESULTS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Liping, Zhao, Juanjuan, Kong, Ning, He, Yan, Hu, Jiazhu, Huang, Fuxi, Han, Jianjun, Cao, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593649/
https://www.ncbi.nlm.nih.gov/pubmed/28915678
http://dx.doi.org/10.18632/oncotarget.18283
_version_ 1783263082032660480
author Lin, Liping
Zhao, Juanjuan
Kong, Ning
He, Yan
Hu, Jiazhu
Huang, Fuxi
Han, Jianjun
Cao, Xiaolong
author_facet Lin, Liping
Zhao, Juanjuan
Kong, Ning
He, Yan
Hu, Jiazhu
Huang, Fuxi
Han, Jianjun
Cao, Xiaolong
author_sort Lin, Liping
collection PubMed
description BACKGROUND: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients. RESULTS: A total of 1,770 patients from 8 clinical trials were included. The incidences of high-grade ILD and QTc prolongation was 2.5% (95% CI 1.7-3.6%), and 2.8% (95% CI 1.8-4.3%), respectively. Meta-analysis demonstrated that the use of ALK-TKIs in NSCLC patients significantly increased the risk of developing high-grade ILD (Peto OR, 3.27, 95%CI: 1.18–9.08, p = 0.023) and QTc prolongation (Peto OR 7.51, 95% CI, 2.16–26.15; p = 0.002) in comparison with chemotherapy alone. MATERIALS AND METHODS: A systematic literature search was performed to identify related citations up to January 31, 2017. Data were extracted, and summary incidence rates, Peto odds ratios (Peto ORs), and 95% confidence intervals (CIs) were calculated. CONCLUSIONS: The use of ALK-TKIs significantly increases the risk of developing high-grade ILD and QTc prolongation in lung cancer patients. Clinicians should pay attention to the risks of severe ILD and QTc prolongation with the administration of these drugs.
format Online
Article
Text
id pubmed-5593649
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55936492017-09-14 Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors Lin, Liping Zhao, Juanjuan Kong, Ning He, Yan Hu, Jiazhu Huang, Fuxi Han, Jianjun Cao, Xiaolong Oncotarget Meta-Analysis BACKGROUND: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients. RESULTS: A total of 1,770 patients from 8 clinical trials were included. The incidences of high-grade ILD and QTc prolongation was 2.5% (95% CI 1.7-3.6%), and 2.8% (95% CI 1.8-4.3%), respectively. Meta-analysis demonstrated that the use of ALK-TKIs in NSCLC patients significantly increased the risk of developing high-grade ILD (Peto OR, 3.27, 95%CI: 1.18–9.08, p = 0.023) and QTc prolongation (Peto OR 7.51, 95% CI, 2.16–26.15; p = 0.002) in comparison with chemotherapy alone. MATERIALS AND METHODS: A systematic literature search was performed to identify related citations up to January 31, 2017. Data were extracted, and summary incidence rates, Peto odds ratios (Peto ORs), and 95% confidence intervals (CIs) were calculated. CONCLUSIONS: The use of ALK-TKIs significantly increases the risk of developing high-grade ILD and QTc prolongation in lung cancer patients. Clinicians should pay attention to the risks of severe ILD and QTc prolongation with the administration of these drugs. Impact Journals LLC 2017-05-29 /pmc/articles/PMC5593649/ /pubmed/28915678 http://dx.doi.org/10.18632/oncotarget.18283 Text en Copyright: © 2017 Lin et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Meta-Analysis
Lin, Liping
Zhao, Juanjuan
Kong, Ning
He, Yan
Hu, Jiazhu
Huang, Fuxi
Han, Jianjun
Cao, Xiaolong
Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
title Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
title_full Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
title_fullStr Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
title_full_unstemmed Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
title_short Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
title_sort meta-analysis of the incidence and risks of interstitial lung disease and qtc prolongation in non-small-cell lung cancer patients treated with alk inhibitors
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593649/
https://www.ncbi.nlm.nih.gov/pubmed/28915678
http://dx.doi.org/10.18632/oncotarget.18283
work_keys_str_mv AT linliping metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors
AT zhaojuanjuan metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors
AT kongning metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors
AT heyan metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors
AT hujiazhu metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors
AT huangfuxi metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors
AT hanjianjun metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors
AT caoxiaolong metaanalysisoftheincidenceandrisksofinterstitiallungdiseaseandqtcprolongationinnonsmallcelllungcancerpatientstreatedwithalkinhibitors